mRNA or non-mRNA vaccines within 6 months. The levels of anti-SARS-CoV-2 S-RBD IgG and NAb were analyzed using the Mindray Immunoassay Analyzer CL-900i. Statistical analysis was conducted using mean comparison and regression analysis. Result The mRNA-1273 vaccine had the highest median levels...
COVID) Limited data, however, exists for the use of ECMO in this population The purpose of this study was to evaluate outcomes between COVID and non- COVID patients receiving venovenous (VV) ECMO METHODS: This was a retrospective review of 15 COVID and 15 non-COVID patients receiving VV...
Qian and colleagues constructed an AF-related lncRNA-mRNA network using the GEO database, identifying 107 lncRNA-mRNA regulatory pairs, of which 91 were gain-of-function pairs and 16 were loss-of-function pairs. Furthermore, they observed that the downstream pathways of these pairs contribute t...
Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of cancers, as well as many other diseases. Over the past decade, substantial effort has b
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants Article Open access 28 June 2021 Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2 Article Open access 14 July 2022 Resistance of SARS-CoV-2 variants to ...
30 The SARS-CoV-2 mRNA vaccine was reported to induce a GC response that is strongly associated with the induction of SARS-CoV-2 binding antibodies and memory B cells.31,32 The GC response lasted at least 12 weeks after the second doses of the vaccine, enabling the generation of robust ...
Vaccine response COVID Seropositive Covaxin Covishield Immune response Antibodies T cells Research in context Evidence before this study We identified 8 primary studies that compared the immunogenicity of the COVID-19 vaccines Covaxin and Covishield, after two doses. Two of these studies were from th...
The mRNA vaccine shows extremely high efficiency (95% and 94.5%). Nonetheless, many severe defects were found requiring harsh low stor- age temperature, and including few patients with fatigue, headaches, muscle and joint pain, fever and other symp- toms after injecting the mRNA-based vaccine ...
Objective:To compare the survival and length of stay of invasive ventilation(IV)with those of non-invasive ventilation(NIV)in patients with COVID-19 acute respiratory distress syndrome in a single hospital from May 2020 to March 2021.Methods:After obtaining approval from the Hospital Director,the ...
Authors’ reply to “Early versus late proning in non-intubated COVID-19 pneumonia” Ramandeep Kaur, J. Brady Scott, David L. Vines & Jie Li Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University Medical Center, 600 S Paulina St, Suite 765, Chicago, IL, USA...